116 related articles for article (PubMed ID: 8834533)
1. Homozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas.
Ono Y; Ueki K; Joseph JT; Louis DN
Acta Neuropathol; 1996; 91(3):221-5. PubMed ID: 8834533
[TBL] [Abstract][Full Text] [Related]
2. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
[TBL] [Abstract][Full Text] [Related]
3. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
[TBL] [Abstract][Full Text] [Related]
4. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
5. P16 deletion and mutation analysis in human brain tumors.
Barker FG; Chen P; Furman F; Aldape KD; Edwards MS; Israel MA
J Neurooncol; 1997 Jan; 31(1-2):17-23. PubMed ID: 9049826
[TBL] [Abstract][Full Text] [Related]
6. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
Ueki K; Ono Y; Henson JW; Efird JT; von Deimling A; Louis DN
Cancer Res; 1996 Jan; 56(1):150-3. PubMed ID: 8548755
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic meningioma versus meningeal hemangiopericytoma: immunohistochemical and genetic markers.
Rajaram V; Brat DJ; Perry A
Hum Pathol; 2004 Nov; 35(11):1413-8. PubMed ID: 15668900
[TBL] [Abstract][Full Text] [Related]
8. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines.
Kelley MJ; Nakagawa K; Steinberg SM; Mulshine JL; Kamb A; Johnson BE
J Natl Cancer Inst; 1995 May; 87(10):756-61. PubMed ID: 7563154
[TBL] [Abstract][Full Text] [Related]
9. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
[TBL] [Abstract][Full Text] [Related]
10. The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor.
Raffel C; Ueki K; Harsh GR; Louis DN
Neurosurgery; 1995 May; 36(5):971-4; discussion 974-5. PubMed ID: 7791990
[TBL] [Abstract][Full Text] [Related]
11. Allelotype analysis in mouse hepatocellular carcinomas; frequent homozygous deletion of mouse homolog of p16/CDKN2 gene on chromosome 4 in culture.
Miyasaka K; Fukui T; Kitagawa T
Biol Pharm Bull; 1996 May; 19(5):683-91. PubMed ID: 8741575
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
[TBL] [Abstract][Full Text] [Related]
13. NF2 gene analysis distinguishes hemangiopericytoma from meningioma.
Joseph JT; Lisle DK; Jacoby LB; Paulus W; Barone R; Cohen ML; Roggendorf WH; Bruner JM; Gusella JF; Louis DN
Am J Pathol; 1995 Nov; 147(5):1450-5. PubMed ID: 7485407
[TBL] [Abstract][Full Text] [Related]
14. Absence of p16 gene (CDKN2) deletions in microdissected primary breast carcinoma specimens.
Calvano JE; Rush EB; Tan LK; Rosen PP; Borgen PI; Van Zee KJ
Ann Surg Oncol; 1997; 4(5):416-20. PubMed ID: 9259969
[TBL] [Abstract][Full Text] [Related]
15. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
[TBL] [Abstract][Full Text] [Related]
16. Meningeal hemangiopericytomas: a clinicopathological study with emphasis on MGMT (O(6) -methylguanine-DNA methyltransferase) promoter methylation status.
Kakkar A; Kumar A; Jha P; Goyal N; Mallick S; Sharma MC; Suri A; Singh M; Kale SS; Julka PK; Sarkar C; Suri V
Neuropathology; 2014 Aug; 34(4):333-42. PubMed ID: 24521400
[TBL] [Abstract][Full Text] [Related]
17. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
[TBL] [Abstract][Full Text] [Related]
18. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
19. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
Dreyling MH; Bullinger L; Ott G; Stilgenbauer S; Müller-Hermelink HK; Bentz M; Hiddemann W; Döhner H
Cancer Res; 1997 Oct; 57(20):4608-14. PubMed ID: 9377576
[TBL] [Abstract][Full Text] [Related]
20. Homozygous deletion of the p16/MTS-1/CDKN2 gene in malignant gliomas is infrequent among Japanese patients.
Mochizuki S; Iwadate Y; Namba H; Yoshida Y; Yamaura A; Sakiyama S; Tagawa M
Int J Oncol; 1999 Nov; 15(5):983-9. PubMed ID: 10536183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
